

VU Research Portal

Surfing the Hippocampus Wave

Bartel, F.

2019

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Bartel, F. (2019). *Surfing the Hippocampus Wave*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy


If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Chapter 3

Inter-observer variation of hippocampus delineation in hippocampal-avoidance prophylactic cranial irradiation



Fabian Bartel
Marcel B. van Herk
Hugo Vrenken
Frederik Vandaele
Stefan Sunaert
Katrien de Jaeger
Nienke J. Dollekamp
Casper Carbaat
Emmy Lamers
Edith M.T. Dieleman
Yolande Lievens
Dirk de Ruyscher
Sanne B. Schagen
Michiel B. de Ruiter
Jan C. de Munck
Jose Belderbos

Abstract

Background: Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) techniques have been developed to reduce radiation damage to the hippocampus. An inter-observer hippocampus delineation analysis was performed and the influence of the delineation variability on dose to the hippocampus was studied.

Materials and Methods: For five patients, seven observers delineated both hippocampi on brain MRI. The intra-class correlation (ICC) with absolute agreement and the generalized conformity index (CI_{gen}) were computed. Median surfaces over all observers' delineations were created for each patient and regional outlining differences were analysed. HA-PCI dose plans were made from the median surfaces and we investigated whether dose constraints in the hippocampus could be met for all delineations.

Results: The ICC for the left and right hippocampus was 0.56 and 0.69 respectively, while the CI_{gen} ranged from 0.55 to 0.70. The posterior and anterior-medial hippocampal regions had most variation with SDs ranging from approximately 1 to 2.5mm. The mean dose (D_{mean}) constraint was met for all delineations, but for the dose received by 1% of the hippocampal volume ($D_{1\%}$) violations were observed.

Conclusion: The relatively low ICC and CI_{gen} indicate that delineation variability among observers for both left and right hippocampus was large. The posterior and anterior-medial border have the largest delineation inaccuracy. The hippocampus D_{mean} constraint was not violated.

3.1. Introduction

Of all lung cancers, about 10-15% are diagnosed as small cell lung cancers (SCLC) [1]. Without radiological or clinical evidence of brain metastases, prophylactic cranial irradiation (PCI) is used to treat microscopic brain metastases and reduce the risk of developing larger metastases [2,3]. It has been shown that PCI in SCLC has a positive effect on overall survival [4,5].

Recent radiation therapy oncology group (RTOG, <https://www.rtog.org/>) studies in patients with SCLC treated with PCI, have observed that PCI could cause short-term, progressive as well as irreversible neurotoxicity leading to cognitive decline [6–8]. Furthermore, a reduction of short term quality of life has been reported [9,10]. Therefore, especially in patients receiving PCI it is important to introduce techniques to prevent neurocognitive toxicity.

The hippocampus is an important archicortical brain structure playing a crucial role in episodic and spatial memory and in neurogenesis [11,12]. Several studies have found that even small doses of radiation can injure the neural stem cell (NSC) compartment located in the dentate gyrus of the hippocampus [13–17].

Based on these findings, the RTOG has performed a phase II hippocampal avoidance (HA) study to investigate the feasibility of this approach in 42 patients [18]. The hippocampus was delineated on structural brain MRI and a 5mm planning organ at risk volume (PRV) margin was placed around the hippocampus defining the 'hippocampal avoidance zone'. This 5mm margin covers the radiosensitive and memory specific neural stem cell compartment. A reduction of mean dose to this compartment by at least 80%, while maintaining dose homogeneity and good coverage to the rest of the brain, was shown to be possible with intensity-modulated radiation therapy (IMRT) techniques in [19]. In this multi-institutional non-randomized phase II RTOG 0933 trial, memory preservation was associated with hippocampal sparing in patients treated with whole brain radiation therapy (WBRT) for brain metastases compared to a historical group that received WBRT without HA [18]. Some studies state that metastasis incidence in the hippocampi, and hippocampus avoidance region is low (about 5%) compared to other parts of the brain [20–22]. Such low incidence is in agreement with its relatively small volumes [23], i.e., it is assumed that distribution of brain metastases in the HA region is not significantly different than in other brain regions [23]. A recent prospective study in 20 patients treated with HA-PCI, has found that one patient developed a metastasis in the HA zone [24], and a recent case study described a patient developing a metastasis in the perihippocampal region seven month after receiving HA-PCI [25]. These studies suggest that hippocampal sparing has the potential to reduce

neurocognitive decline, but the risk of development of brain metastases in the spared region also needs to be considered. Evaluating the risk and benefit of hippocampus sparing PCI is the subject of on-going phase III trials, which are investigating neurocognitive functioning in patients treated with PCI or HA-PCI, including an international study hosted by the Netherlands Cancer Institute (NCT01780675). Hippocampus sparing radiotherapy treatment planning techniques were introduced in the last few years [19,26,27].

Due to the low grey value contrast with adjacent structures [28] precise hippocampus delineation on MRI scans is difficult. Therefore, hippocampus sparing techniques can be expected to suffer from delineation variability among radiation oncologists and technicians. However, until now the precise influence of delineation inaccuracy has not been studied in depth. Therefore, it is currently unknown how precise hippocampus delineation is, and how accurate it needs to be for successful hippocampus avoidance strategies. In this study, we determine whether the accuracy of hippocampus delineation by radiation oncologists or technicians is high enough to meet the hippocampus dose constraints for patients treated within the Dutch-Belgian randomized phase III HA-PCI trial (NCT01780675).

3.2. Materials and Methods

Patients' and observers' characteristics

Four radiation oncologists, two radiation technicians and one neuroradiologist were recruited from different centers in the Netherlands and Belgium. The observers delineated the hippocampus on five patient datasets (2 women and 3 men), selected from a multicenter phase III trial where patients with SCLC are randomized to receive standard PCI or HA-PCI treatment (Clinical trials.gov identifier: NCT01780675). The mean patient age was 62 years, range 51-71. The observers were instructed to follow the RTOG-atlas hippocampus outlining protocol [29], but had little experience in hippocampus delineation. MRI and CT scans for each patient were collected at the Netherlands Cancer Institute in Amsterdam, the Netherlands. The MRI acquisition protocol was adopted from the Alzheimer's Disease Neuroimaging Initiative (ADNI, <http://adni.loni.usc.edu>), which investigated MRI protocols to capture the brain morphometry with minimum patient burden. A detailed description of the MRI acquisition protocol be found in [30]. MRI scans of the cerebrum were acquired with a sagittal 3D T1 weighted magnetization prepared rapid gradient echo (MP-RAGE) sequence using 3T. All MRIs had an in-plane square pixel size of 1mm² and a slice thickness of 1.2mm. Treatment-planning CT scans of the brain had a slice spacing of 1mm with in-plane pixel sizes between 0.6 and 0.7mm².

Following the RTOG guidelines, the MRI scans were rigidly registered and resampled to the CT scans using the bony anatomy and using in-house software (WorldMatch) [31]. Registered MRI and CT scans were distributed in DICOM format to the different centers and the left and right hippocampus were delineated on the resliced MRI scans. Delineated hippocampal contours could be defined at in-plane sub-pixel level. To obtain 3D closed surface meshes, 2D contours on consecutive slices were connected with straight lines.

Furthermore, we asked each observer to fill out a questionnaire to rate their delineation experience in years or number of previously performed hippocampus delineations, delineation time and to judge the difficulty for each delineation (easy, moderate or difficult).

Inter-rater delineation comparison

For each subject, hippocampus delineations of the seven observers were compared by determining hippocampal volumes and reporting the intra-class correlation coefficient (ICC) with absolute agreement in a two-way mixed model. The ICC for absolute agreement is defined as the ratio between the variance due to subjects and the total variance. To determine the overlap of observers' delineations, the generalized conformity index (CI_{gen}) [32] was computed. CI_{gen} is defined by:

$$CI_{gen} = \frac{\sum_{pairs\ ij} |A_i \cap A_j|}{\sum_{pairs\ ij} |A_i \cup A_j|} \quad (1)$$

with A_i representing delineated structures. To compute CI_{gen} , hippocampal surface meshes were converted to voxel-wise segmentations. Interpolation errors were minimized by enclosing all surfaces with a fine regular grid [33]. Hippocampus segmentations were then approximated by marking voxels inside the hippocampal meshes.

Next, as described by Steenbakkens et al. [34] a median surface for each hippocampus of the same patient was created, where each point inside the median surface is designated by at least 50% of all observers' hippocampus delineations (Fig. 1). Then, a delineation variability analysis was performed by calculating the perpendicular distance from each point of the median surface to each observer's delineation [34]. Local observer variation was expressed by calculating the standard deviation (SD) at each point of the median surface using the seven observers' distances.




Fig. 1: Example of observers' delineated right hippocampus on MRI and median surface (black) in a) axial, b) sagittal and c) coronal view. Turquoise: radiation oncologist; Magenta: neuroradiologist; Green: radiation oncologist; Yellow: radiation technician; White: radiation technician; Red: radiation oncologist; Purple: radiation oncologist.

Dose plan evaluation

We exported the five median surfaces and corresponding treatment planning CT scans to the treatment planning system, Pinnacle³ version 9 (Philips Medical Systems, Eindhoven, The Netherlands). Using these, volumetric modulated arc therapy (VMAT) hippocampus sparing radiotherapy plans were generated. According to the trial protocol (NCT01780675), for the HA arm a dose of 25Gy in 10 fractions was prescribed to the planning target volume (PTV) defined as the whole brain plus 4mm margin minus the PRV. The PRV was the hippocampus delineation plus 5mm margin. The percentage volume of the PTV which was determined to receive 95% and 115% of the prescription dose ($V_{95\%PTV}$ and $V_{115\%PTV}$) was $\geq 95\%$ and $\leq 1\%$ respectively. The doses delivered to 98% and 1% of the PTV ($D_{98\%PTV}$ and $D_{1\%PTV}$) were to be $\geq 18.75\text{Gy}$ and $\leq 27.5\text{Gy}$ respectively. The maximum dose received by the PTV ($D_{\max PTV}$) was set to $\leq 28.75\text{Gy}$. The mean dose constraint to the left and right hippocampus (D_{mean}) was $\leq 8.5\text{Gy}$, which correlates to a mean biological dose ($D_{\text{mean biological}}$) of $\leq 6.2\text{Gy}$ ($\alpha/\beta=2\text{Gy}$). The dose received by 1% ($D_{1\%}$) of the left and right hippocampal volume was set to be $\leq 10\text{Gy}$ and the maximal dose for the eye lenses was $\leq 10\text{Gy}$.

We transferred all hippocampus delineations to the generated HA-PCI VMAT dose plans generated on the median surface and computed the organ at risk constraints described above for all hippocampus delineations to observe if all dose constraints could be met in spite of observer variation.

3.3. Results

Delineation variability

The average hippocampal volumes for each observer ranged for the left hippocampus from 1.51cm³ to 2.36cm³ and for the right hippocampus from 1.73cm³ to 2.36cm³. For the median surfaces, mean left and right hippocampal volumes were 1.99cm³ and 2.16cm³ respectively. The left median hippocampus surface was on average visible on 16 – 17 slices (range: 11-21 slices) and the right hippocampus was visible on 17-18 slices (range: 15-20 slices). All observers' left and right hippocampal volumes and volumes of the median hippocampal surfaces, together with means and SDs, are presented in supplementary Table 1. In Fig. 2 corresponding volumes are illustrated graphically. The ICC with absolute agreement was 0.56 and 0.69 for the left and right hippocampus, respectively. Table 1 shows the CI_{gen} , ranging from 0.55 to 0.70.




Fig. 2: Left and right hippocampal volumes in cm³ for observers' hippocampus delineations and the median surfaces. Turquoise: radiation oncologist; Magenta: neuroradiologist; Green: radiation oncologist; Yellow: radiation technician; White: radiation technician; Red: radiation oncologist; Purple: radiation oncologist.

Table 1: The generalized conformity index (CI_{gen}) results for the left and right hippocampus.

Pat. #	CI_{gen}	
	Left	Right
1	0.65	0.63
2	0.55	0.61
3	0.64	0.70
4	0.61	0.63
5	0.60	0.61

Pat. # Patient number,

CI_{gen} Generalized conformity index

Local shape variation between outlines from different observers was projected onto the median surface for each patient and each hippocampus (Fig. 3). It can be seen that for both left and right hippocampus the posterior and anterior-medial border have the largest inter-observer variation with SDs ranging from approximately 1-2.5mm.




Fig. 3: Local shape variation in mm projected on the median surfaces of each patient for left (top) and right (bottom) hippocampus. For each point of the median surface the distance to each observer's delineation was determined and the SD of all seven distances was projected. From the most posterior to the most anterior point the hippocampus is approximately 3.5cm long.

Five of the seven observers filled out the questionnaires. The radiation oncologists and technicians only had little (5 previous hippocampus delineations) or no delineation experience. The neuroradiologist rated his experiences as ten years but did not use the RTOG protocol for hippocampus delineation before. The delineation time ranged from 10-25min with an average of 16min. Most hippocampi were rated as moderately hard to delineate. One of the observers commented that the posterior and medial border were difficult to delineate.

Planning organ at risk volumes and dose plan results

The mean left PRV volumes ranged from 13.74cm³ to 17.04cm³ and the mean right PRV volumes from 14.42cm³ to 17.40cm³. The mean left and right PRV volumes of the median surface were 14.74cm³ and 15.48cm³ respectively. All PRV volumes are presented in the supplementary files in Suppl. Table 2 and in Suppl. Fig. 1.

Dose parameters for the PTV of the VMAT plans obtained using the median surfaces are summarized in Table 2. For all five patients the dose constraints and constraints for the eye lenses could be met. In patient 5, the D_{max} constraint seems exceeded, but this occurs in a single pixel in air, which is considered irrelevant.

Table2: Dose parameters for the PTV of each patient.

Parameter	Pat. #1	Pat. #2	Pat. #3	Pat. #4	Pat. #5	Dose constraint
$V_{95\%PTV}$	95%	95%	95%	95%	95%	$\geq 95\%$
$V_{115\%PTV}$	0%	0%	0%	0%	0%	$\leq 1\%$
$D_{98\%PTV}$	19.9Gy	19.6Gy	20.1Gy	20.4Gy	20Gy	$\geq 18.75Gy$
$D_{1\%PTV}$	26.8Gy	27.5Gy	27.3Gy	26.5Gy	27.2Gy	$\leq 27.5Gy$
D_{maxPTV}	28.7Gy	28.6Gy	28.5Gy	28.1Gy	28.9Gy	$\leq 28.75Gy$
$D_{meanPTV}$	25.2Gy	25.8Gy	25.5Gy	25.0Gy	25.4Gy	

Pat. # Patient number, *PTV* Planning target volume, $V_{95\%PTV}$ & $V_{115\%PTV}$ 95% and 115% of the prescription dose received by the PTV, $D_{98\%PTV}$ & $D_{1\%PTV}$ Doses delivered to 98% and 1% of the PTV, D_{maxPTV} & $D_{meanPTV}$ Maximum and mean does received by the PTV

All D_{mean} , $D_{mean\ biological}$ and the $D_{1\%}$ planned to the hippocampus are presented in Fig. 4 for all patients and observers delineations. The dashed lines in these bar plots represent the dose constraint value for the given parameter. For most hippocampus delineations the dose constraints could be met, however a few outliers can be observed in the hippocampus $D_{1\%}$. For those outliers, parts of the delineations deviated too much from the median surfaces and therefore the $D_{1\%}$ is above the constraint.




Fig. 4: Planned dose to the hippocampus presented for each patient according to each observers' delineation. The dashed horizontal lines are the trial constraints for the hippocampus. Top: Mean dose planned to the hippocampus (Dmean). Middle: Calculated mean biological dose to the hippocampus (Dmean biological). Bottom: Dose planned by one percent of the hippocampal volume (D1%). Observer 1: radiation oncologist; Observer 2: neuroradiologist; Observer 3: radiation oncologist; Observer 4: radiation technician; Observer 5: radiation technician; Observer 6: radiation oncologist; Observer 7: radiation oncologist.

3

3.4. Discussion

In this study we analyzed hippocampus delineation variability in seven observers and reported the influence of this variability on the dose distribution.

So far, only one abstract, by Diwanji et al., was published comparing hippocampus delineations of three different observers in patients with brain metastases [35]. Their conclusion was that hippocampus delineations had fairly high concordance with mean hippocampal volumes of 2.30-2.62cm³, slightly larger than our mean hippocampal volumes 1.62-2.36cm³. Differences between left and right hippocampal volumes and observer's delineation experience were not reported. According to the abstract, hippocampi were delineated on two different sets of MRIs with two different sequences. Recent atlases were used for delineation, but no reference was given. Therefore, it is difficult to compare our results with theirs.

The difference between average left and right hippocampal volumes can be confirmed with other literature in which hippocampal volumes were measured on structural MRI in neuroradiology [33,36–39]. In our inter-observer variation analysis, we grouped delineations of the radiation oncologists, technicians and the neuroradiologist together, because of the relatively small number of raters per expertise group. Moreover, raters roughly showed the same level of experience in using the RTOG outlining protocol. With ICCs of 0.56 and 0.69 for the left and right hippocampus respectively our volume correlations scores are relatively low compared to hippocampus segmentations performed in neuroradiology, where inter-observer variability scores are usually higher than 0.85 [40]. Of note, in neuroradiology experts are trained to delineate the hippocampus accurately because the aim is often a precise volume measurement. The CI_{gen} is a numerical extension of the Jaccard index for multiple observers, and a Jaccard index of 0.67 is considered to reflect relatively good accuracy for a small structure such as the hippocampus [41]. Our CI_{gen} scores ranged from 0.55 to 0.70, indicating that the observer delineation variation is large. We did not consider the delineation of the neuroradiologist as the “gold standard”, because of his/her limited experience in using the RTOG outlining protocol.

One reason for the high observer variation in our study could be the inexperience of the observers in delineating the hippocampus. In this context, the instructions of the RTOG protocol might not be clear enough as it depicts and describes hippocampal boundaries on an MRI in axial direction only. Extending this protocol to a description of hippocampal boundaries in coronal and sagittal direction may help improving observer's hippocampus delineation. Furthermore, the RTOG atlas describes a hippocampus delineation on “optimal” MR brain images. Delineating the

hippocampus on brain images of elderly patients with SCLC is more difficult, because the MRI scans can be prone to artefacts and brain anatomy can differ due to age related atrophy. Finally, Di Biase et al. showed that the head position on the treatment table can affect hippocampal appearance. To solve the problem they developed a practical guide for hippocampus delineation based on three different head position set ups [42].

We computed local shape variation and showed that most delineation inaccuracy appeared in the posterior and anterior-medial borders (SD range: 1-2.5mm). These regions were also mentioned by one observer in the questionnaires as difficult to delineate. This is most probably due to similar grey value intensities of adjacent structures. The RTOG-atlas hippocampus outlining protocol describes to exclude the fimbria, which was included in some cases. Furthermore, part of the amygdala was sometimes taken into the delineation. Therefore, it may be helpful to switch from axial to sagittal view if possible in those regions to improve consistency. This observation might help to improve the delineation protocol, by adding non-axial images for these boundaries. Furthermore, there is considerable shorter delineation time reported for our study (~16min) compared to the reported hippocampus segmentation performed in neuroradiology (~2h [43]). A multidisciplinary delineation procedure by adding expertise from trained neuroradiologists could be considered for training purposes and to improve hippocampus delineation. For instance, in the field of Alzheimer's and dementia it has been shown that training positively increased delineation accuracy [25]. Another approach may be to organize central review platforms to support and improve delineation in the real-life setting. The Belgian College for physicians in radiation oncology has finalized two such projects, for rectal and for breast cancer, which resulted in increased uniformity of clinical target volume delineation per center and at national level [44,45]. Such quality assurance projects may safeguard the benefits of HA-PCI in the broader population, even if the dosimetry impact in this study seems limited.

In this study we created median hippocampus delineations from all observers' delineations to estimate delineations being closer to the ground truth. The resulting VMAT dose plans were used to evaluate if all dose constraints for each observer's delineation could be met. All dose constraints of the trial for D_{mean} and $D_{\text{mean biological}}$ were met for all observers' hippocampus delineations. For completeness, we also reported violations of the hippocampus $D_{1\%}$ constraint, but this constraint is considered of less importance in hippocampal avoidance dose planning. Our dose analysis shows that hippocampal delineation accuracy is not crucial to fulfil the trial protocol (NCT01780675) dose constraints, given the current PRV margin of 5mm. However, more accurate hippocampus delineations might allow a reduction of the PRV margin in the future. Such a reduction would reduce the peri-hippocampal

volume receiving lower dose than prescribed and it might lower the chance that metastases develop. There is about a factor 6 difference in volume between PRV and hippocampus, indicating that each mm margin reduction would reduce under-dosed brain significantly.

To reduce manual outlining labor, applying automatic or semi-automatic contouring methods to delineate the hippocampus might also be an interesting option. For instance, FSL-FIRST [46] and FreeSurfer [28,47] are well known public available segmentation methods, used in numerous studies [33,48–52]. There are also recent developments reported towards multi-atlas segmentation methods, where lot of work is dedicated to reduce the registration time for such methods [53,54]. As we have shown, even if hippocampus delineation would differ from the “ground truth”, hippocampal dose constraints can still be met. Validating (semi-)automatic delineation methods in this context would be highly desirable.

3.5. Conclusion

Even though substantial inter-observer delineation variation was observed, for hippocampi the required dose constraints for all observers' delineations were met due to applied PRV margin. We think that hippocampus delineation could be improved by adjusting the RTOG-atlas protocol and by adding expertise from neuroradiology. Improving hippocampus delineation accuracy might allow reducing the PRV margin.

Supplementary data

Suppl. Table 1: Left and right hippocampal volumes for all observers' delineations and the median surfaces in cm3. Observer 1: radiation oncologist; Observer 2: neuroradiologist; Observer 3: radiation oncologist; Observer 4: radiation technician; Observer 5: radiation technician; Observer 6: radiation oncologist; Observer 7: radiation oncologist.

Pat. #	Hippo-campus	Observer							Median
		1	2	3	4	5	6	7	
1	Left	2.14	2.41	2.48	1.74	2.11	2.40	2.07	2.13
2	Left	1.79	2.20	2.07	1.45	1.99	2.23	2.14	2.00
3	Left	1.81	1.84	2.25	1.52	2.26	1.55	1.73	1.80
4	Left	2.00	1.84	2.69	1.33	1.67	1.72	2.16	1.86
5	Left	2.31	2.14	2.33	1.53	2.83	2.21	2.32	2.18
1	Right	2.65	2.30	2.47	1.96	2.24	2.74	2.32	2.31
2	Right	1.85	1.96	2.11	1.85	2.15	1.88	2.17	1.97
3	Right	1.92	2.00	2.27	1.65	2.19	2.04	1.96	2.02
4	Right	2.20	1.86	2.70	1.66	2.12	2.42	2.42	2.15
5	Right	2.43	2.26	2.23	1.54	2.92	2.71	2.48	2.33
Mean	Left	2.01	2.09	2.36	1.51	2.17	2.02	2.08	1.99
(SD)	Left	(±0.221)	(±0.243)	(±0.233)	(±0.151)	(±0.427)	(±0.365)	(±0.219)	(±0.166)
	Right	2.27	2.36	2.33	1.73	2.36	2.08	2.21	2.16
	Right	(±0.208)	(±0.388)	(±0.337)	(±0.172)	(±0.233)	(±0.194)	(±0.339)	(±0.161)


Pat. # Patient number, SD Standard deviation

Suppl. Table 2: Left and right PRV volumes for all observers' and the median PRV volumes in cm3. Observer 1: radiation oncologist; Observer 2: neuroradiologist; Observer 3: radiation oncologist; Observer 4: radiation technician; Observer 5: radiation technician; Observer 6: radiation oncologist; Observer 7: radiation oncologist.

Pat. #	Hippo-campus	Observer							Median
		1	2	3	4	5	6	7	
1	Left	15.7	16.9	18.5	14.9	16.8	18.2	15.3	15.6
2	Left	14	15.9	16	13.4	15.2	17.1	16.4	14.2
3	Left	13.9	14.8	16.1	12.9	15.3	13.8	14.3	13.6
4	Left	15.3	15.3	18.1	12.9	13.8	15.3	16.2	14.5
5	Left	15.9	16.8	16.5	14.6	18.6	16.9	17.1	15.8
1	Right	17.4	16.4	18.1	15.6	17.5	19.1	16.6	16.2
2	Right	13.8	14.7	15.5	14.2	14.9	15.1	15.8	14.2
3	Right	14.9	15.8	16.1	13.8	15.9	16.4	15.6	14.9
4	Right	15.8	14.5	19.4	14.9	13.9	17.5	17.2	15.6
5	Right	17.1	17.6	16.6	13.6	18.5	18.9	18	16.5
Mean	Left	14.96	15.94	17.04	13.74	15.94	16.26	15.86	14.74
(SD)	Left	(±0.948)	(±0.918)	(±1.174)	(±0.950)	(±1.827)	(±1.721)	(±1.083)	(±0.937)
	Right	15.80	15.80	17.14	14.42	16.14	17.40	16.64	15.48
	Right	(±1.505)	(±1.275)	(±1.588)	(±0.826)	(±1.873)	(±1.691)	(±0.994)	(0.942)

Pat. # Patient number, SD Standard deviation





Suppl. Fig. 1: Left and right PRV volumes in cm³ for observers' hippocampus delineations and the median surfaces. Turquoise: radiation oncologist; Magenta: neuroradiologist; Green: radiation oncologist; Yellow: radiation technician; White: radiation technician; Red: radiation oncologist; Purple: radiation oncologist.

References

- [1] Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. *J Clin Oncol* 2006;24:4539–44.
- [2] Gondi V, Tomé WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. *Radiother Oncol* 2010;97:370–6.
- [3] Péchoux C Le, Sun A, Slotman BJ, De Ruyscher D, Belderbos J, Gore EM. Prophylactic cranial irradiation for patients with lung cancer. *Lancet Oncol* 2016;17:e277–93.
- [4] Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. *N Engl J Med* 1999;341:476–84.
- [5] Slotman B, Faivre-Finn C. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med* 2007;357:664–72.
- [6] Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease . *Int J Radiat Oncol Biol Phys* 2011;81:77–84.
- [7] Gondi V, Paulus R, Bruner DW, Meyers CA, Gore EM, Wolfson A, et al. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. *Int J Radiat Oncol Biol Phys* 2013;86:656–64.
- [8] Le Péchoux C, Laplanche A, Faivre-Finn C, Ciuleanu T, Wanders R, Lerouge D, et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). *Ann Oncol Off J Eur Soc Med Oncol* 2011;22:1154–63.
- [9] Slotman BJ, Mauer ME, Bottomley A, Faivre-Finn C, Kramer GWPM, Rankin EM, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. *J Clin Oncol* 2009;27:78–84.
- [10] Groen HJM, Dingemans A-MC, Belderbos J, Tissing-Tan C, Herder G, Haitjema T, et al. Prophylactic cranial irradiation (PCI) versus observation in radically treated stage III non-small cell lung cancer (NSCLC): A randomized phase III NVALT11 study. *J Clin Oncol* 2017;35:abstract 8502.
- [11] Burgess N, Maguire EA, O’Keefe J. The Human Hippocampus and Spatial and Episodic Memory. *Neuron* 2002;35:625–41.
- [12] Deng W, Aimone JB, Gage FH. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? *Nat Rev Neurosci* 2010;11:339–50.
- [13] Ferrer I, Serrano T, Alcantara S, Tortosa A, Graus F. X-ray-induced cell death in the developing hippocampal complex involves neurons and requires protein synthesis. *J Neuropathol Exp Neurol* 1993;52:370–8.

- [14] Raber J, Rola R, LeFevour A, Morhardt D, Curley J, Mizumatsu S, et al. Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. *Radiat Res* 2004;162:39–47.
- [15] Nagai R, Tsunoda S, Hori Y, Asada H. Selective vulnerability to radiation in the hippocampal dentate granule cells. *Surg Neurol* 2000;53:503-6; discussion 506-7.
- [16] Madsen TM, Kristjansen PEG, Bolwig TG, Wörtwein G. Arrested neuronal proliferation and impaired hippocampal function following fractionated brain irradiation in the adult rat. *Neuroscience* 2003;119:635–42.
- [17] Mizumatsu S, Monje ML, Morhardt DR, Rola R, Palmer TD, Fike JR. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. *Cancer Res* 2003;63:4021–7.
- [18] Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): A phase II multi-institutional trial. *J Clin Oncol* 2014;32:3810–6.
- [19] Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, et al. Hippocampal-sparing whole-brain radiotherapy: a “how-to” technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys* 2010;78:1244–52.
- [20] Ghia A, Tomé WA, Thomas S, Cannon G, Khuntia D, Kuo JS, et al. Distribution of Brain Metastases in Relation to the Hippocampus: Implications for Neurocognitive Functional Preservation. *Int J Radiat Oncol Biol Phys* 2007;68:971–7.
- [21] Gondi V, Tome WA, Marsh J, Struck A, Ghia A, Turian J V., et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. *Radiother Oncol* 2010;95:327–31.
- [22] Kundapur V, Ellchuk T, Ahmed S, Gondi V. Risk of Hippocampal Metastases in Small Cell Lung Cancer Patients at Presentation and After Cranial Irradiation: A Safety Profile Study for Hippocampal Sparing During Prophylactic or Therapeutic Cranial Irradiation. *Radiat Oncol Biol* 2015;91:781–6.
- [23] Kesteren Z Van, Olszewska A, Belderbos J, Vliet-Vroegindewei C Van. The distribution of brain metastases in the perihippocampal region (Regarding Gondi et al., *Radiother Oncol* 2010;95:327-331). *Radiother Oncol* 2011;98:144.
- [24] Redmond KJ, Hales RK, Anderson-Keightly H, Zhou XC, Kummerlowe M, Sair HI, et al. Prospective Study of Hippocampal-Sparing Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys* 2017;98:603–11.
- [25] Duchesne S, Valdivia F, Robitaille N, Mouiha A, Valdivia FA, Bocchetta M, et al. Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project. *Alzheimer's Dement* 2015;11:161–74.
- [26] Hsu F, Carolan H, Nichol A, Cao F, Nuraney N, Lee R, et al. Whole Brain Radiotherapy With Hippocampal Avoidance and Simultaneous Integrated Boost for 1-3 Brain Metastases: A Feasibility Study Using Volumetric Modulated Arc Therapy. *Int J Radiat Oncol Biol Phys* 2010;76:1480–5.
- [27] Gutiérrez AN, Westerly DC, Tomé WA, Jaradat HA, Mackie TR, Bentzen SM, et al. Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. *Int J Radiat Oncol Biol Phys* 2007;69:589–97.

- [28] Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. *Neuron* 2002;33:341–55.
- [29] Gondi V, Tome WA, Rowley HA, Mehta MP. Hippocampal Contouring : A Contouring Atlas for RTOG 0933 n.d. <https://www.rtog.org/CoreLab/ContouringAtlases/HippocampalSparing.aspx> (accessed September 25, 2017).
- [30] Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. *J Magn Reson Imaging* 2008;27:685–91.
- [31] Wolthaus JWH, van Herk M, Muller SH, Belderbos JSA, Lebesque J V, de Bois JA, et al. Fusion of respiration-correlated PET and CT scans: correlated lung tumour motion in anatomical and functional scans. *Phys Med Biol* 2005;50:1569–83.
- [32] Kouwenhoven E, Giezen M, Struikmans H. Measuring the similarity of target volume delineations independent of the number of observers. *Phys Med Biol* 2009;54:2863–73.
- [33] Bartel F, Vrenken H, Bijma F, Barkhof F, Van Herk M, De Munck JC. Regional analysis of volumes and reproducibilities of automatic and manual hippocampal segmentations. *PLoS One* 2017;12:e0166785.
- [34] Steenbakkens RJHM, Duppen JC, Fitton I, Deurloo KEI, Zijp LJ, Comans EFI, et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: A three-dimensional analysis. *Int J Radiat Oncol Biol Phys* 2006;64:435–48.
- [35] Diwanji T, Snider JW, Koroulakis A, Feigenberg SJ, Mohindra P, Kwok Y, et al. Interobserver Variability in Atlas-Based, Manual Segmentation of the Hippocampus in Patients With Brain Metastases. *Int J Radiat Oncol • Biol • Phys* 2016;96:E130.
- [36] Barnes J, Foster J, Boyes RG, Pepple T, Moore EK, Schott JM, et al. A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus. *Neuroimage* 2008;40:1655–71.
- [37] Basso M, Yang J, Warren L, MacAvoy MG, Varma P, Bronen RA, et al. Volumetry of amygdala and hippocampus and memory performance in Alzheimer's disease. *Psychiatry Res Neuroimaging* 2006;146:251–61.
- [38] Jack CR, Jr., Slomkowski M, Gracon S, Hoover TM, Felmler JP, et al. MRI as a Biomarker of Disease Progression in a Therapeutic Trial of Milameline for AD. *Neurology* 2003;60:253.
- [39] Wenger E, Mårtensson J, Noack H, Bodammer NC, Kühn S, Schaefer S, et al. Comparing manual and automatic segmentation of hippocampal volumes: reliability and validity issues in younger and older brains. *Hum Brain Mapp* 2014;35:4236–48.
- [40] Boccardi M, Ganzola R, Bocchetta M, Pievani M, Redolfi A, Bartzokis G, et al. Survey of protocols for the manual segmentation of the hippocampus: Preparatory steps towards a joint EADC-ADNI harmonized protocol. *Adv Alzheimer's Dis* 2011;2:111–25.
- [41] Dill V, Franco AR, Pinho MS. Automated methods for hippocampus segmentation: the evolution and a review of the state of the art. *Neuroinformatics* 2015;13:133–50.
- [42] Di Biase S, Trignani M, Caravatta L, Voicu PI, Di Carlo C, Vinciguerra A, et al. Development of a contouring guide in three different head set-ups for hippocampal sparing radiotherapy: a practical approach. *Radiol Med* 2017;122:683–9.
- [43] Carmichael OT, Aizenstein HA, Davis SW, Becker JT, Thompson PM, Meltzer CC, et al. Atlas-based hippocampus segmentation in Alzheimer's disease and mild cognitive impairment.

- Neuroimage 2005;27:979–90.
- [44] Kindts I, Vandermeulen A, Verhoeven K, Laenen A, Hortobágyi E, Weltens CG. A Central Review Platform Improves the Quality of Regional Lymph Node Delineation for Breast Cancer Radiation Therapy. *Int J Radiat Oncol* 2016;96:E38–9.
 - [45] Joye I, Lambrecht M, Jegou D, Hortobágyi E, Scalliet P, Haustermans K. Does a central review platform improve the quality of radiotherapy for rectal cancer? Results of a national quality assurance project. *Radiother Oncol* 2014;111:400–5.
 - [46] Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. *Neuroimage* 2011;56:907–22.
 - [47] Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. *Neuroimage* 2012;61:1402–18.
 - [48] Morey R a., Petty CM, Xu Y, Pannu Hayes J, Wagner HR, Lewis D V., et al. A comparison of automated segmentation and manual tracing for quantifying hippocampal and amygdala volumes. *Neuroimage* 2009;45:855–66.
 - [49] Morey RA, Selgrade ES, Wagner HR, Huettel SA, Wang L, McCarthy G. Scan-rescan reliability of subcortical brain volumes derived from automated segmentation. *Hum Brain Mapp* 2010;31:1751–62.
 - [50] Pardoe HR, Pell GS, Abbott DF, Jackson GD. Hippocampal volume assessment in temporal lobe epilepsy: How good is automated segmentation? *Epilepsia* 2009;50:2586–92.
 - [51] Doring TM, Kubo TT a, Cruz LCH, Jurueña MF, Fainberg J, Domingues RC, et al. Evaluation of hippocampal volume based on MR imaging in patients with bipolar affective disorder applying manual and automatic segmentation techniques. *J Magn Reson Imaging* 2011;33:565–72.
 - [52] Mulder ER, de Jong R a., Knol DL, van Schijndel R a., Cover KS, Visser PJ, et al. Hippocampal volume change measurement: Quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST. *Neuroimage* 2014;92:169–81.
 - [53] Wang H, Suh JW, Das SR, Pluta JB, Craige C, Yushkevich PA. Multi-Atlas Segmentation with Joint Label Fusion. *IEEE Trans Pattern Anal Mach Intell* 2013;35:611–23.
 - [54] Zhu H, Cheng H, Yang X, Fan Y, Alzheimer’s Disease Neuroimaging Initiative. Metric Learning for Multi-atlas based Segmentation of Hippocampus. *Neuroinformatics* 2017;15:41–50.

